p-Ethyl phenoxy-triethyl amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: p-Ethyl phenoxy-triethyl amine
• 英文别名: N,N-diethyl-2-(4-ethylphenoxy)ethanamine
• 化学式: C₁₄H₂₃NO
• mdl: MFCD01468165
• 分子量: 221.34
• InChiKey: LLDMYGZAFRIZRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：giraFpharma LLC

  公开号：US20190106436A1

  公开（公告）日：2019-04-11

  Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Wee1抑制剂的杂环化合物。这些化合物可能被用作治疗药物，用于治疗疾病，并且可能在肿瘤学中发挥特定作用。
• ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS
  申请人：Parker F. Michael

  公开号：US20080085894A1

  公开（公告）日：2008-04-10

  There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R 1 , R 2 and R 3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.

  提供了一系列新型α-(N-磺酰胺基)乙酰胺化合物的公式(I)，其中R、R1、R2和R3在此定义，它们是β-淀粉样肽（β-AP）产生的抑制剂，并且在治疗阿尔茨海默病和其他受到抗淀粉样蛋白活性影响的疾病中有用。
• SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE
  申请人：Gregan Fridrich

  公开号：US20100125076A1

  公开（公告）日：2010-05-20

  Substituted sulphonamides having the general formula (I) and salts, hydrates and solvates thereof were prepared and described, wherein R 1 is CO or SO 2 and R 2 is NH or O and where R represents linear or cyclic aliphatic chain and n represents number of linking aliphatic chain carbons (n can be 0, 1, 2 or 3), which are useful in the manufacture of the medicaments due to the carboanhydrase inhibition. These compounds are prepared by nucleophilic reaction of an amine with 4-sulfamoylbenzenesulphonyl chloride in the presence of triethylamine excess in tetrahydrofurane or in ether at temperature 0 to 20° C. The compounds show an antiglaucomatic activity.

  制备并描述了具有通式（I）及其盐、水合物和溶剂化合物的取代磺酰胺，其中R1为CO或SO2，R2为NH或O，R代表线性或环状脂肪链，n代表连接脂肪链碳数（n可以为0、1、2或3），由于碳酸酐酶抑制作用，这些化合物在药物制造中非常有用。这些化合物通过在四氢呋喃或醚中以0至20°C的温度下，在三乙胺过量存在下的氨与4-磺酰基苯磺酰氯的亲核反应制备而成。这些化合物表现出抗青光眼活性。
• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2975042A1

  公开（公告）日：2016-01-20

  The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

  本发明涉及一种对酪氨酸激酶具有抑制活性的新型融合嘧啶衍生物，以及一种用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病或免疫介导疾病的药物组合物，该药物组合物的有效成分包括嘧啶衍生物。
• Heterocyclic compounds and uses thereof
  申请人：NUVATION BIO INC.

  公开号：US10807994B2

  公开（公告）日：2020-10-20

  Heterocyclic compounds of Formula (I): as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  式 (I) 的杂环化合物： 提供了作为 Wee1 抑制剂的杂环化合物。这些化合物可用作治疗疾病的药物，尤其可用于肿瘤学。